Citation: Jy. Reginster et al., Correct regimen of fluoride and calcium reduces the risk of vertebral fractures in postmenopausal osteoporosis, OSTEOPOR IN, 12(9), 2001, pp. 800-800
Citation: I. Setnikar et Lc. Rovati, Absorption, distribution, metabolism and excretion of glucosamine sulfate - A review, ARZNEI-FOR, 51(9), 2001, pp. 699-725
Authors:
Setnikar, I
Schmid, K
Rovati, LC
Vens-Cappell, B
Mazur, D
Kozak, I
Citation: I. Setnikar et al., Bioavailability and pharmacokinetic profile of dihydroergotoxine from a tablet and from an oral solution formulation, ARZNEI-FOR, 51(1), 2001, pp. 2-6
Citation: A. Santoro et al., Assessment of skin safety of a new glyceryl trinitrate transdermal patch -Animal and human studies, ARZNEI-FOR, 51(1), 2001, pp. 29-37
Citation: Lc. Rovati et al., Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study, GYNECOL END, 14(4), 2000, pp. 282-291
Authors:
Santoro, A
Rovati, LC
Setnikar, I
Caplain, H
Gualano, V
Citation: A. Santoro et al., Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch, ARZNEI-FOR, 50(9), 2000, pp. 779-785
Authors:
Santoro, A
Rovati, LC
Follet, M
Setnikar, I
Caplain, H
Gualano, V
Citation: A. Santoro et al., Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch, ARZNEI-FOR, 50(9), 2000, pp. 786-794
Authors:
Miglio, F
Rovati, LC
Santoro, A
Setnikar, I
Citation: F. Miglio et al., Efficacy and Safety of Oral Betaine Glucuronate in Non-alcoholic steatohepatitis - A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study, ARZNEI-FOR, 50(8), 2000, pp. 722-727
Authors:
De Aloysio, D
Rovati, LC
Giacovelli, G
Setnikar, I
Bottiglioni, F
Citation: D. De Aloysio et al., Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches - A randomized, double-blind placebo-controlled study, ARZNEI-FOR, 50(3), 2000, pp. E293-E300
Authors:
Santoro, A
Rovati, LC
Lanzini, R
Setnikar, I
Citation: A. Santoro et al., Pharmaceutical development and characteristics of a new glyceryl trinitrate transdermal patch, ARZNEI-FOR, 50(10), 2000, pp. 897-903
Authors:
Setnikar, I
Rovati, LC
Santoro, A
Guillaume, M
Mignot, A
Renoux, A
Gualano, V
Citation: I. Setnikar et al., Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch, ARZNEI-FOR, 49(8), 1999, pp. 708-715
Authors:
Rovati, LC
Schmid, K
Giacovelli, G
Bonn, M
Setnikar, I
Wolff, F
Genazzani, AR
Citation: Lc. Rovati et al., Efficacy on climacteric symptoms of a new estradiol transdermal patch withactive matrix in comparison with a reference reservoir patch - Two long-term randomized multicenter parallel-group studies, ARZNEI-FOR, 49(11), 1999, pp. 933-943
Authors:
De Aloysio, D
Rovati, LC
Giacovelli, G
Setnikar, I
Bottiglioni, F
Citation: D. De Aloysio et al., Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches, 9TH INTERNATIONAL MENOPAUSE SOCIETY WORLD CONGRESS ON THE MENOPAUSE, 1999, pp. 173-176
Citation: Lc. Rovati et al., Dose-response efficacy of a new estradiol transdermal matrix patch for a 7-day application, 9TH INTERNATIONAL MENOPAUSE SOCIETY WORLD CONGRESS ON THE MENOPAUSE, 1999, pp. 233-237
Authors:
Setnikar, I
Rovati, LC
Schmid, K
Vens-Cappell, B
Barkworth, MF
Citation: I. Setnikar et al., Bioavailability and pharmacokinetic characteristics of two monofluorophosphate preparations with calcium supplement, ARZNEI-FOR, 48(12), 1998, pp. 1172-1178